METGEN - The Art of Biocatalysis
MetGen Oy, Itäinen Pitkäkatu 4 B, 20520 Turku, Finland, info@metgen.fi
Home Products Services Technology Investor Relations Contact Us
LATEST NEWS

23.06.2009
MetGen is exhibiting at CPHI Worldwide 2009 which will take place in Madrid, 13-15 October 2009.

20.06.2009
MetGen expands service offering to address growing customer needs in.

15.06.2009
MetGen presented at Invest Tech 2009in Helsinki

01.06.2009
MetGen focuses on Laccase process development using toolbox of MetGen laccases.

ALL NEWS


Company Vision & Strategy

White biotechnology has the capacity to change industrial biotechnology processes. For example, 75% of pharmaceutical active compounds are chiral compounds and the best way to make these efficiently is through biotech processes. A cheap source of compounds for the pharma industry is vital to its competitiveness.

Bioprocesses already account for 15 million tons a year of chemical products including organic and amino acids, antibiotics, industrial and food enzymes, fine chemicals as well as active ingredients for crop protection, pharmaceutical products and fuel ethanol.

White biotechnology can generate real revenue. White biotechnology also has an enormous potential because 99 percent of all microorganisms are still unknown.

White biotechnology represents "a window of opportunity". Manufacturing financially viable and environmentally compatible products using MetGen's proprietary technology - is an opportunity not to be missed

Pharmaceutical, Chemical and Forest industries are facing the similar challenges today
  • Improving of chemical production efficiency
  • Rising oil prices
  • Need for environmentally friendly production processes
There is need for new cheaper and cleaner routes to produce chemicals. Biocatalysis and industrial enzymes are a common solution.

MetGen Oy is a Finnish company active in development and production of biopharmaceuticals and industrial enzymes for pharmaceutical industry. MetGen biocatalytical processes make the production of pharmaceuticals and industrial products faster, cleaner and less expensive.

MetGen and its customers will benefit from turning low margin / high waste chemical production in to high margin/low waste biotransformation process.

By using biotransformation methods provided by MetGen manufacturing can reduce the costs for about 70%.

MetGen Strategy

  • Fast development of new enzymes
  • Implementation of new economically and environmentally friendly bioprocesses
  • Turning low margin / high waste chemical production into high margin / low waste biotransformation process

MetGen addresses pyramid of market need by offering novel bioprocesses



COMPANY

Company Vision & Strategy
Management and Board of Directors
Competitive Advantage